| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Black Diamond Therapeutics, Inc. | Officer Title: President and Chief Executive Officer, Director | Common Stock | 671K | $1.83M | $2.73 | Jun 27, 2023 | Direct |
| Black Diamond Therapeutics, Inc. | Officer Title: President and Chief Executive Officer, Director | Common Stock | 16.6K | $45.3K | $2.73 | Jun 27, 2023 | Indirect |
| GYRE THERAPEUTICS, INC. | Director | Stock Option (Right to Buy) | 52K | Aug 14, 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| GYRE | GYRE THERAPEUTICS, INC. | Aug 14, 2024 | 1 | $0 | 4 | Aug 16, 2024 | Director |
| GYRE | GYRE THERAPEUTICS, INC. | Aug 6, 2024 | 1 | $0 | 4 | Aug 8, 2024 | Director |
| GYRE | GYRE THERAPEUTICS, INC. | Aug 6, 2024 | 0 | $0 | 3 | Aug 8, 2024 | Director |
| BDTX | Black Diamond Therapeutics, Inc. | Jun 27, 2023 | 1 | -$168K | 4 | Jun 28, 2023 | Officer Title: President and Chief Executive Officer, Director |
| BDTX | Black Diamond Therapeutics, Inc. | Feb 13, 2023 | 1 | $0 | 4 | Feb 15, 2023 | Officer Title: President and Chief Executive Officer, Director |
| BDTX | Black Diamond Therapeutics, Inc. | Feb 15, 2022 | 1 | $0 | 4 | Feb 17, 2022 | Officer Title: President and Chief Executive Officer, Director |